沃森生物(300142.SZ):新型冠狀病毒變異株mRNA疫苗(Omicron XBB.1.5)獲批納入緊急使用
格隆匯12月1日丨沃森生物(300142.SZ)公佈,公司與復旦大學、上海藍鵲生物醫藥有限公司(簡稱“上海藍鵲”)合作研發的新型冠狀病毒變異株mRNA疫苗(Omicron XBB.1.5)(簡稱“RQ3033疫苗”或“該疫苗”),於2023年12月1日收到國務院聯防聯控機制科研攻關組疫苗研發專班的函件,經國家相關部門批准納入緊急使用。
RQ3033疫苗是基於公司與復旦大學、上海藍鵲共同建立的mRNA技術平台,在一代疫苗即新型冠狀病毒變異株mRNA疫苗(S蛋白嵌合體)(以下簡稱“RQ3013疫苗”)基礎上研發的迭代疫苗。該疫苗是針對當前新冠病毒OmicronXBB設計的單價疫苗,符合世界衞生組織最新推薦優先使用含OmicronXBB抗原組分的單價新冠疫苗的建議。
RQ3033疫苗適用於18歲及以上人羣,用於預防當前新冠病毒主要流行株OmicronXBB、EG.5等引起的疾病(COVID-19)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.